AI In Point-of-Care Hematology Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global AI In Point-of-Care Hematology Market Trends and Insights

Rapid Bedside CBC Demand in Acute and Ambulatory Care

Rapid bedside hematology is becoming critical as emergency and ambulatory teams require immediate blood count results to make treatment decisions. The AI in point-of-care hematology market is benefiting from this demand, with advanced analyzers delivering multi-parameter blood counts from fingerstick or low-volume samples in minutes. This capability is particularly impactful in oncology follow-ups, monitoring immunosuppressed patients, and urgent triage, where delays can disrupt patient flow and increase repeat visits. The introduction of AI-supported testing devices for near-patient use highlights the shift toward decentralized diagnostics, enabling faster and more efficient decision-making. Providers are also leveraging this technology to transition routine blood monitoring to care sites previously reliant on central laboratories.

Rising Burden of Anemia, Infection, and Hematologic Disease

The growing prevalence of anemia, infections, oncology cases, and hematologic diseases is driving demand for AI in point-of-care hematology. Clinical validation of AI-supported analyzers in pediatric oncology demonstrated over 98.9% classification accuracy and Cohen’s kappa values above 0.95, proving their reliability in high-frequency testing. These systems also offer cost advantages, making them suitable for clinics and resource-limited settings. Additionally, AI devices for sepsis triage have shown superior performance compared to traditional markers, achieving a bacterial infection AUROC of 0.83 and enhanced sensitivity for ICU-level care. These advancements are building trust in AI tools for both routine and critical care applications.

Miniaturized Cartridge and Capillary Sampling Adoption

Miniaturization is a key driver in the AI in point-of-care hematology market, simplifying workflows and reducing dependency on bulky instruments. Cartridge-based and low-volume sampling designs enable easy deployment in decentralized settings, allowing non-specialist staff to operate the systems efficiently. For example, advanced devices now deliver a 5-part differential complete blood count from a single drop of blood in about 5 minutes. Certification processes that streamline compliance across multiple markets further enhance scalability, enabling faster international rollouts. These innovations align product designs with the operational needs of smaller care sites, making the technology more accessible and practical.

Expansion of Decentralized Diagnostics in APAC and Emerging Markets

The AI in point-of-care hematology market is expanding rapidly in Asia-Pacific, driven by high disease burdens, limited laboratory access, and efforts to bring diagnostics closer to patients. In Japan, the implementation of AI workflow solutions reduced over 7,600 work hours within four months, showcasing the efficiency gains from automation.^{[1]Yuki Matsuoka, “Current Status and Issues of AI Equipped SaMD Including Hematology Systems,” Journal of Medical Laboratory Technology, jstage.jst.go.jp} This growth reflects a broader shift toward decentralized diagnostics, emphasizing workflow redesign and the ability to manage increasing test volumes with fewer manual steps. The market's momentum in emerging regions highlights a structural transformation rather than a simple replacement of existing systems in tertiary hospitals.

Accuracy Validation Gap Versus Central Laboratory Workflows

A critical challenge in the AI-driven point-of-care hematology market is ensuring that capillary or point-of-care test results meet the reliability standards of high-throughput central laboratory systems. Despite strong concordance results, accredited reporting environments demand method comparisons, precision assessments, and consistent evidence across sites. Commercial adoption depends on validation against established laboratory quality benchmarks, and compliance with ISO 15189 adds complexity. Smaller companies face hurdles as they often lack the resources or infrastructure to support extensive validation programs, slowing their market entry.

LIS Interoperability and Cybersecurity Compliance at Decentralized Sites

Interoperability remains a significant barrier, as many hospitals still use laboratory information systems designed for older analyzers and outdated messaging protocols. Modern devices with cloud-based architectures or alternative data exchange methods require site-specific configurations, creating deployment challenges. Additionally, stricter cybersecurity requirements demand robust controls over patient data processing and AI model deployment. Success in this market increasingly depends on secure integration with hospital digital systems, highlighting the importance of aligning technological advancements with operational infrastructure.

Segment Analysis

By Product: Consumables Revenue Poised to Challenge Instrument Dominance

In 2025, systems dominated the product structure with 38.2% of revenue, reflecting capital spending trends and the demand for validated analyzer platforms in hospitals. The systems category benefits from hospital procurement cycles and service contracts, with instrument placement often determining consumables in workflows. Consumables and reagents are projected to grow at a robust 25.05% CAGR through 2031, driven by cartridge-based and closed-test designs that shift recurring spending to individual test events.

By Test Type: CBC Anchors Volume While Hemoglobin Testing Drives Incremental Growth

Complete blood count (CBC) testing contributed 39.78% of test-type revenue in 2025, maintaining its position as the volume anchor in the AI-driven point-of-care hematology market. CBC’s broad clinical applications, including infection assessment, anemia workup, oncology monitoring, and pre-surgical screening, sustain its market dominance. Hemoglobin and hematocrit testing, supported by demand from anemia screening and sickle-cell monitoring, is the fastest-growing test type, with a 25.76% CAGR forecast through 2031.

By Technology & AI Capability: Optical Leadership Remains Strong While Flow Cytometry Gains Speed

Optical and imaging-based analysis accounted for 55.72% of revenue in 2025, underscoring the dominance of AI-augmented image cytometry. These systems excel in morphology-heavy tasks, identifying features like blast cells and red blood cell shape variations. Flow cytometry-based analysis is expected to grow at 26.15% CAGR through 2031, driven by advancements in miniaturized fluidics that enable sophisticated methods in compact devices.

By End User: Hospitals Lead While Diagnostic Laboratories Expand Faster

Hospitals represented 46.1% of revenue in 2025, driven by the need for rapid blood count data in emergency departments, oncology units, and outpatient clinics. Diagnostic laboratories are forecast to grow at 26.75% CAGR through 2031, reflecting a shift toward same-day service models and faster turnaround times. Laboratory networks increasingly prioritize connected workflows and data-driven insights alongside analytical performance.

Geography Analysis

In 2025, North America commanded a dominant 44.32% share of the revenue in the AI-driven point-of-care hematology market. This leadership is supported by a strong regulatory framework, enhanced reimbursement for near-patient testing, and significant investments in hospital and outpatient care. The February 2026 clearance of Athelas Home under a CLIA-waived pathway further strengthened the region's position by enabling AI-powered testing in decentralized care settings. North America's focus on faster patient routing and quicker monitoring continues to make it a key launch market for innovations in this sector.

While Europe plays a crucial role in adoption, the pace varies across nations and healthcare settings. Western European markets are advancing in AI-supported digital morphology and workflow modernization, while other regions remain in early stages of integration. The February 2026 certification of Scopio Labs' AI-powered platforms under EU IVDR regulations expanded access across the EU. Europe's growth in this market depends on how quickly hospitals and laboratories transition from pilot programs to routine workflows.

Asia-Pacific is on track to witness a robust 27.25% CAGR growth rate through 2031, making it the fastest-growing region in the AI-driven point-of-care hematology market. Growth is driven by healthcare decentralization, rising demand for community diagnostics, and local manufacturers catering to regional needs. Operational changes in Japan highlight this trend, with significant efficiency gains reported after deploying AI solutions in laboratory operations. Simpler point-of-care platforms also address service gaps in areas with limited laboratory access, while community clinics and primary care networks serve as key entry points for adoption in emerging regions.